All In Biotech

Drug Trial Radar · NCT00063479

Bisphosphonate Treatment of Osteogenesis Imperfecta

Last checked: Nov 20, 2026Latest source record: Jun 1, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 158 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

158

Actual

Start

Jun 2003

Primary completion

May 2007

Study completion May 2007

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Jun 30, 2003

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 3 months, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this trial is to evaluate whether the investigational medication is safe, effective and has the ability to increase spine bone density in osteogenesis imperfecta (OI) patients.

Conditions

  • Osteogenesis Imperfecta

Interventions

  • Zoledronic AcidDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in lumbar spine bone mineral density at month 12 relative to baseline

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • UCLA - Division of Pediatric Nephrology

    Los Angeles, California

  • Alfred I. DuPont Hospital for Children

    Wilmington, Delaware

  • Intermountain Orthopedics

    Boise, Idaho

  • St. Jude Children's Research Hospital

    Peoria, Illinois

  • Children's Hospital

    Omaha, Nebraska

  • Children's Hospital Medical Center

    Cincinnati, Ohio

  • Children's Hospital

    Columbus, Ohio

  • Oregon Health Sciences University

    Portland, Oregon

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • Texas Children's Hosptial

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.